Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Immunomedics reports positive study of cancer drug

By Drug Discovery Trends Editor | August 14, 2013

Shares of Immunomedics jumped Wednesday after announcing that its treatment for a type of non-Hodgkin lymphoma helped to extend the lives of patients that used it in combination with another drug.

The company said patients with newly diagnosed follicular lymphoma responded well to a combination of its epratuzumab and Roche’s drug, Rituxan. Patients who took the drug regimen lived about 3.5 years prior to death or disease progression on average. Immunomedics said about 60% of the patients are still alive three years after being treated.

Follicular lymphoma is a slow growing type of non-Hodgkin lymphoma, a cancer that affects the lymphatic system. The epratuzumab-Rituxan regimen is being studied as a treatment for newly diagnosed cases of the disease. Immunomedics said Rituxan and chemotherapy can improve survival in those patients, but many patients can’t tolerate the side effects of chemotherapy or don’t want to try it.

Immunomedics reported results from 59 patients in the mid-stage trial. The company said 25 of the patients went into complete remission after treatment and 27 had a partial response to treatment.

Shares of Immunomedics Inc. gained 8 cents to $5.06 at midday. The stock rose as much as 7.2% in morning trading.

Immunomedics has no approved drugs. It has epratuzumab to UCB SA as a treatment for conditions other than cancer, and UCB is conducting late-stage testing of the drug as a treatment for lupus.


Filed Under: Drug Discovery

 

Related Articles Read More >

EVEREST lead investigator on why Dupixent sets a new bar for treating coexisting CRSwNP and asthma
Sanders, King target DTC pharma ads but the industry worries more about threats to its $2B R&D model
Zoliflodacin wins FDA nod for treatment of gonorrhea
FDA approved ENFLONSIA for the prevention of RSV in Infants
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE